I have written before that “90% of the progress being made today is concentrated in 10% of the cancers.” And the majority of the 10% are made up of hematological (blood) cancers–leukemia, lymphoma and multiple myeloma.
Why? Because blood cancers tend to respond best to chemotherapy–and chemo is what oncologists do!
So it only makes sense that drug manufacturers, the ones who pay for most research studies, would try successful blood cancer chemotherapy drugs on other forms of cancer. I don’t know if the industry has created a formal term for this or not. I call it “crossover chemotherapy.”
Sometimes it works–often it doesn’t. But several chemotherapy drugs used successfully against multiple myeloma are now being tried against a variety of other cancers. I can already tell a large amount of research data being released at this year’s ASCO will deal with crossover chemo.
Look for some of these crossovers in my next post–an article about Millennium’s non-multiple myeloma related presentations at ASCO.
Feel good and keep smiling! Pat